KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $48.7 million.

  • Supernus Pharmaceuticals' Cash from Investing Activities rose 16324.55% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.8 million, marking a year-over-year increase of 11758.89%. This contributed to the annual value of -$189.9 million for FY2024, which is 17065.37% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Cash from Investing Activities stood at $48.7 million, which was up 16324.55% from -$30.6 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Cash from Investing Activities ranged from a high of $239.8 million in Q1 2023 and a low of -$82.2 million during Q3 2022
  • For the 5-year period, Supernus Pharmaceuticals' Cash from Investing Activities averaged around -$8.6 million, with its median value being -$30.6 million (2025).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Cash from Investing Activities crashed by 134165.5% in 2022 and then surged by 48456.53% in 2023.
  • Supernus Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $76.1 million in 2021, then plummeted by 164.05% to -$48.8 million in 2022, then crashed by 35.3% to -$66.0 million in 2023, then soared by 80.85% to -$12.6 million in 2024, then soared by 485.39% to $48.7 million in 2025.
  • Its Cash from Investing Activities was $48.7 million in Q3 2025, compared to -$30.6 million in Q2 2025 and $37.3 million in Q1 2025.